Most Recent Articles by Lauren Burke
Brentuximab Vedotin Approved for Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-expressing Mycosis FungoidesNov 10, 2017
The U.S. Food and Drug Administration has approved brentuximab vedotin for the treatment of adult patients with pcALCL or CD30-expressing mycosis fungoides who have received prior systemic therapy.
The FDA has granted alectinib (ALECENSA) accelerated approval for the treatment of patients with non-small cell lung cancer.
Using a genotype-guided dose of fluoropyrimidine in DPYD*2A variant allele carriers significantly reduced grade 3 or higher toxicities.
As of 2012 in the U.S. there were 14 million cancer survivors, a number that is expected to grow to 18 million by 2022.
The FDA announced approval of CYRAMZA (ramucirumab) for use in combination with FOLFIRI for metastatic colorectal cancer.
More Articles by Lauren Burke
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment
- Do Additional Chromosomal Abnormalities Noted at CML Diagnosis Affect Response and Survival?
- Does Education Level Predict PSA Screening and Prostate Cancer Survival?
- Pembrolizumab May Benefit Selected Patients With Incurable Metastatic Breast Cancer
- Unrelated HSCT, UCBT May Yield Similar Survival Outcomes in Acute Leukemia
- Adjuvant Gefitinib Improves Disease-free Survival Among Patients With NSCLC
- Phase 1 Study of Binimetinib Plus Pexidartinib for GIST
- Phase 2 Study of Nivolumab vs Nivolumab Plus Ipilimumab for GIST
- Pesticides and Cancer
- Goserelin Mitigates Risk of Ovarian Failure, Improves Breast Cancer Survival Rate